The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1658
ISSUE1658
September 5, 2022
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
September 5, 2022 (Issue: 1658)
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.